Anupam Rasayan India Limited (ANURAS) — Announcement | 3 June 2026

· NSE 🔴 High Importance Neutral

Anupam Rasayan India Limited announced that Crisil Ratings upgraded its bank loan facilities to Rs. 1620 crore (from Rs. 1369.82 crore) and assigned a Crisil A+/Watch Developing rating to non-convertible debentures of Rs. 160 crore, both placed on Watch Developing. The rating action follows the company's planned acquisition of a 43.3-48.2% stake in Bliss GVS Pharma, which will likely be funded through debt and equity. Crisil noted the group's strong market position and diversified revenue streams but highlighted risks from working capital intensity and foreign exchange volatility. The company's revenue rose to Rs. 2,365 crore in fiscal 2026 from Rs. 1,439 crore in fiscal 2025, though operating margins declined to 22.19% from 27.67%.

📄 View Original Announcement (PDF)

About Anupam Rasayan India Limited (ANURAS)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

Market Cap: ₹15,665.53 Cr P/E: 68.4 ROE: 6.0% ROCE: 9.7%

View full ANURAS stock details →

📡 Get AI alerts when ANURAS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ANURAS — Free

📊 More ANURAS filings

See all ANURAS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when ANURAS files new disclosures

Track ANURAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ANURAS — Free

Free account · 2 AI queries/day